Literature DB >> 30178242

Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.

Ferga C Gleeson1, Michael J Levy2.   

Abstract

PURPOSE OF REVIEW: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-associated mortality with continued poor outcome and a short-lived treatment response to conventional therapy. However, with the rapidly evolving field of precision oncology, new and novel genomic information is emerging, identifying tumor subtypes by revealing somatic and germline mutations. RECENT
FINDINGS: There is growing interest in determining the tumor BRCA status to guide potential PARP inhibitor targeted therapy and for evaluating tumor microsatellite instability status for immune checkpoint inhibitor therapy which has been reported in up to 3% of PDAC patients. Precision immuno-oncology and therapies targeting the stroma are a developing oncologic field but to date the impact upon patients with PDAC has not been established. The ability to complete tumor genotyping and gene expression assessments and to determine immunotherapy eligibility have renewed optimism that patients with PDAC may soon have access to effective treatment strategies.

Entities:  

Keywords:  BRCA; Immune checkpoint inhibitors; Immuno-oncology; PARP inhibitors; Pancreatic ductal adenocarcinoma; RNA sequencing; Tumor microenvironment

Year:  2018        PMID: 30178242     DOI: 10.1007/s11938-018-0195-x

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  18 in total

1.  Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Davendra P S Sohal; Erin B Kennedy; Alok Khorana; Mehmet S Copur; Christopher H Crane; Ignacio Garrido-Laguna; Smitha Krishnamurthi; Cassadie Moravek; Eileen M O'Reilly; Philip A Philip; Ramesh K Ramanathan; Joseph T Ruggiero; Manish A Shah; Susan Urba; Hope E Uronis; Michelle W Lau; Daniel Laheru
Journal:  J Clin Oncol       Date:  2018-05-23       Impact factor: 44.544

2.  BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.

Authors:  Alex B Blair; Vincent P Groot; Georgios Gemenetzis; Jishu Wei; John L Cameron; Matthew J Weiss; Michael Goggins; Christopher L Wolfgang; Jun Yu; Jin He
Journal:  J Am Coll Surg       Date:  2018-01-05       Impact factor: 6.113

3.  Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.

Authors:  Maeve A Lowery; Emmet J Jordan; Olca Basturk; Ryan N Ptashkin; Ahmet Zehir; Michael F Berger; Tanisha Leach; Brian Herbst; Gokce Askan; Hannah Maynard; Danielle Glassman; Christina Covington; Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; David S Klimstra; Jaclyn F Hechtman; David M Hyman; Peter J Allen; William R Jarnagin; Vinod P Balachandran; Anna M Varghese; Mark A Schattner; Kenneth H Yu; Leonard B Saltz; David B Solit; Christine A Iacobuzio-Donahue; Steven D Leach; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

4.  Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Authors:  Zishuo I Hu; Jinru Shia; Zsofia K Stadler; Anna M Varghese; Marinela Capanu; Erin Salo-Mullen; Maeve A Lowery; Luis A Diaz; Diana Mandelker; Kenneth H Yu; Alice Zervoudakis; David P Kelsen; Christine A Iacobuzio-Donahue; David S Klimstra; Leonard B Saltz; Ibrahim H Sahin; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2018-01-24       Impact factor: 12.531

5.  Hypermutation In Pancreatic Cancer.

Authors:  Jeremy L Humphris; Ann-Marie Patch; Katia Nones; Peter J Bailey; Amber L Johns; Skye McKay; David K Chang; David K Miller; Marina Pajic; Karin S Kassahn; Michael C J Quinn; Timothy J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Craig Nourse; Ehsan Nourbakhsh; Andrew Stone; Peter J Wilson; Matthew Anderson; J Lynn Fink; Oliver Holmes; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Ronald S Mead; Qinying Xu; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Adnan M Nagrial; Venessa T Chin; Lorraine A Chantrill; Amanda Mawson; Angela Chou; Christopher J Scarlett; Andreia V Pinho; Ilse Rooman; Marc Giry-Laterriere; Jaswinder S Samra; James G Kench; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Nigel B Jamieson; Colin J McKay; C Ross Carter; Euan J Dickson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Jennifer P Morton; Owen J Sansom; Robert Grützmann; Ralph H Hruban; Anirban Maitra; Christine A Iacobuzio-Donahue; Richard D Schulick; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Borislav Rusev; Vincenzo Corbo; Roberto Salvia; Ivana Cataldo; Giampaolo Tortora; Margaret A Tempero; Oliver Hofmann; James R Eshleman; Christian Pilarsky; Aldo Scarpa; Elizabeth A Musgrove; Anthony J Gill; John V Pearson; Sean M Grimmond; Nicola Waddell; Andrew V Biankin
Journal:  Gastroenterology       Date:  2016-11-15       Impact factor: 22.682

6.  NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

Authors:  Christoph Heining; Peter Horak; Sebastian Uhrig; Paula L Codo; Barbara Klink; Barbara Hutter; Martina Fröhlich; David Bonekamp; Daniela Richter; Katja Steiger; Roland Penzel; Volker Endris; Karl Roland Ehrenberg; Stephanie Frank; Kortine Kleinheinz; Umut H Toprak; Matthias Schlesner; Ranadip Mandal; Lothar Schulz; Helmut Lambertz; Sebastian Fetscher; Michael Bitzer; Nisar P Malek; Marius Horger; Nathalia A Giese; Oliver Strobel; Thilo Hackert; Christoph Springfeld; Lars Feuerbach; Frank Bergmann; Evelin Schröck; Christof von Kalle; Wilko Weichert; Claudia Scholl; Claudia R Ball; Albrecht Stenzinger; Benedikt Brors; Stefan Fröhling; Hanno Glimm
Journal:  Cancer Discov       Date:  2018-05-25       Impact factor: 39.397

Review 7.  Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development.

Authors:  Stephan B Dreyer; David K Chang; Peter Bailey; Andrew V Biankin
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

8.  Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:  Andrew J Aguirre; Jonathan A Nowak; Nicholas D Camarda; Richard A Moffitt; Arezou A Ghazani; Mehlika Hazar-Rethinam; Srivatsan Raghavan; Jaegil Kim; Lauren K Brais; Dorisanne Ragon; Marisa W Welch; Emma Reilly; Devin McCabe; Lori Marini; Kristin Anderka; Karla Helvie; Nelly Oliver; Ana Babic; Annacarolina Da Silva; Brandon Nadres; Emily E Van Seventer; Heather A Shahzade; Joseph P St Pierre; Kelly P Burke; Thomas Clancy; James M Cleary; Leona A Doyle; Kunal Jajoo; Nadine J McCleary; Jeffrey A Meyerhardt; Janet E Murphy; Kimmie Ng; Anuj K Patel; Kimberly Perez; Michael H Rosenthal; Douglas A Rubinson; Marvin Ryou; Geoffrey I Shapiro; Ewa Sicinska; Stuart G Silverman; Rebecca J Nagy; Richard B Lanman; Deborah Knoerzer; Dean J Welsch; Matthew B Yurgelun; Charles S Fuchs; Levi A Garraway; Gad Getz; Jason L Hornick; Bruce E Johnson; Matthew H Kulke; Robert J Mayer; Jeffrey W Miller; Paul B Shyn; David A Tuveson; Nikhil Wagle; Jen Jen Yeh; William C Hahn; Ryan B Corcoran; Scott L Carter; Brian M Wolpin
Journal:  Cancer Discov       Date:  2018-06-14       Impact factor: 39.397

9.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.

Authors:  Sunil R Hingorani; William P Harris; J Thaddeus Beck; Boris A Berdov; Stephanie A Wagner; Eduard M Pshevlotsky; Sergei A Tjulandin; Oleg A Gladkov; Randall F Holcombe; Ronald Korn; Natarajan Raghunand; Samuel Dychter; Ping Jiang; H Michael Shepard; Craig E Devoe
Journal:  Clin Cancer Res       Date:  2016-01-26       Impact factor: 12.531

Review 10.  Emerging strategies in BRCA-positive pancreatic cancer.

Authors:  Adam Kowalewski; Łukasz Szylberg; Michał Saganek; Wojciech Napiontek; Paulina Antosik; Dariusz Grzanka
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-18       Impact factor: 4.553

View more
  1 in total

1.  The Dual Role of HMGB1 in Pancreatic Cancer.

Authors:  Rui Kang; Daolin Tang
Journal:  J Pancreatol       Date:  2018-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.